This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or docetaxel combined with trastuzumab and pertuzumab, respectively.
Subjects voluntarily enrolled in this study with good compliance
Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0-1
HER2 positive, recurrent or metastatic invasive breast cancer confirmed by histopathology or cell pathology
Defined hormone receptor (HR) status
It is known that there is spinal cord compression or active central nervous system metastasis;
Subjects with only skin and/or brain lesions as target lesions
Combined diseases and medical history
Have had or currently have other malignant tumors within the past 5 years of randomization